AstraZeneca (AZN) Tops Q2 EPS by 93c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AstraZeneca (AZN) Appoints Michel Demare as Incoming Board Chair
July 29, 2022 5:57 AM EDTAstraZeneca (NASDAQ: AZN) today announced the appointment of Michel Demaré as the Chair-designate of the Board.
His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior independent Non-Executive Director.
As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the conclusion of the Companys Annual General Meeting in April 2023. Michels... More
